口服表达mSEB的枯草芽孢杆菌减少小鼠肠道金黄色葡萄球菌定植
该研究在小鼠模型中口服重组mSEB枯草芽孢杆菌孢子三次每周共三周,随后口服灌胃1×10^9 CFU金黄色葡萄球菌(ATCC 14458)进行攻击。结果显示mSEB免疫与SEB特异性黏膜和全身抗体升高、全身炎症减轻、肠道菌群改变及攻击后肠道金黄色葡萄球菌负荷降低相关。
要点
- 口服mSEB孢子可诱导SEB特异性粪便sIgA及血清IgG1、IgG2a升高(P<0.01)。
- 攻击后第3天mSEB组粪便金黄色葡萄球菌负荷低于对照组和CotC组。
- mSEB免疫降低腹腔巨噬细胞促炎因子转录并改变肠道菌群。
核心结论
- 口服表达mSEB的枯草芽孢杆菌孢子与SEB特异性黏膜和全身抗体应答、全身炎症减轻、肠道菌群改变及攻击后肠道金黄色葡萄球菌负荷降低相关,但因果机制尚待阐明。
研究设计与样本
- 小鼠口服重组mSEB孢子每周三次共三周,免疫后口服灌胃1×10^9 CFU金黄色葡萄球菌(ATCC 14458)攻击,检测抗体、巨噬细胞因子、16S rRNA测序、RNA-seq及粪便菌负荷。
主要发现
- 口服mSEB孢子与升高的全身和黏膜SEB特异性IgG1、IgG2a及粪便sIgA相关(P<0.01)。
- 攻击后mSEB小鼠腹腔巨噬细胞TNF-α、IL-6和IL-1β转录降低,与全身炎症减轻一致。
- mSEB免疫改变肠道菌群并增加Barnesiella相对丰度。
- 肠道RNA-seq显示mSEB组富集抗原呈递和B细胞受体信号基因集。
- 攻击后第3天粪便金黄色葡萄球菌负荷:对照24.20±3.967×10^4 CFU,CotC 8.081±3.614×10^4 CFU,mSEB 3.6±1.030×10^4 CFU。
临床怎么用
- 该策略尚处小鼠研究阶段,提示口服孢子疫苗或可作为降低肠道金黄色葡萄球菌定植的潜在预防手段,但需进一步临床验证。
局限性
- 原文指出这些变化背后的因果机制尚待阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: S. aureus intestinal colonization elevates infection risk, underscoring decolonization as a key prevention target. SEB is a key target for the development of neutralizing antibodies against toxins to prevent and treat S. aureus infection. B. subtilis is used as a probiotic for human health. OBJECTIVE: To investigate the efficacy of recombinant mSEB B. subtilis spores for reducing S. aureus intestinal colonization in mouse. METHODS: Mice were orally immunized with recombinant mSEB spores three times a week for three weeks. After immunization, mice were challenged via oral gavage with 1 × 109 CFU of S. aureus (ATCC 14458). Fecal specific IgA and serum IgG1 and IgG2a were analyzed by ELISA. Peritoneal macrophages were isolated for qRT-PCR analysis of TNF-α, IL-6 and IL-1β mRNA expression. Colon contents samples underwent 16S rRNA sequencing for microbiota profiling. Intestinal RNA was extracted for transcriptome sequencing (RNA-seq), and differential pathways were analyzed using KEGG enrichment. Body weight and fecal viable S. aureus burden were monitored. RESULTS: Oral mSEB spores correlated with elevated systemic and mucosal SEB-specific IgG1, IgG2a and fecal sIgA (P < 0.01). After S. aureus challenge, peritoneal macrophages from mSEB mice showed lower pro-inflammatory TNF-α, IL-6 and IL-1β transcripts, consistent with attenuated systemic inflammation. mSEB immunization also altered gut microbiota and increased the relative abundance of Barnesiella. Intestinal RNA-seq identified enriched antigen presentation and B cell receptor signaling gene sets in the mSEB group. On day 3 post-challenge, fecal S. aureus loads were 24.20 ± 3.967 × 104 CFU (Control), 8.081 ± 3.614 × 104 CFU (CotC) and 3.6 ± 1.030 × 104 CFU (mSEB), showing a pathogen-clearing phenotype linked to mSEB treatment. CONCLUSION: Immunization with mSEB-displaying Bacillus subtilis spores correlates with SEB-specific mucosal and systemic antibody responses, blunted systemic inflammation, modified gut microbiota, and reduced intestinal S. aureus burdens post-challenge. The causal mechanisms underlying these changes remain to be clarified.
引用
- Yang K, He Y, Zhou X, et al. Oral delivery of recombinant Bacillus subtilis expressing mSEB reduces intestinal Staphylococcus aureus colonization. Vaccine. 2026. PMID: 42472494. doi:10.1016/j.vaccine.2026.128939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。